Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buyuan Zhixiao Formula for Elderly Diabetes and Metabolic Disorders
NCT06358118Not yet recruiting
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 1
01
Overview
Randomised, double-blind trial of Buyuan Zhixiao Formula in type 2 diabetes mellitus (T2DM), metabolic syndrome and cognitive impairment (2 arms). Primary endpoint: Hemoglobin A1c at 12 months. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
Buyuan Zhixiao Formula
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic syndromecognitive impairment
Beyond the preview
Go deeper on NCT06358118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06358118.